Résultats de la recherche - Tsai, Max
- Résultat(s) 1 - 16 résultats de 16
-
1
-
2
Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol par Tsai, Max, Case, Michael, Ardayfio, Paul, Hochstetler, Helen, Wilbraham, Darren
Publié 2020Texte -
3
A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor par Tsai, Max, Chrones, Lambros, Xie, Jinhui, Gevorkyan, Hakop, Macek, Thomas A.
Publié 2016Texte -
4
A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis par Naik, Himanshu, Tsai, Max C., Fiedler-Kelly, Jill, Qiu, Ping, Vakilynejad, Majid
Publié 2013Texte -
5
The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus par Dudkowski, Caroline, Tsai, Max, Liu, Jie, Zhao, Zhen, Schmidt, Eric, Xie, Jeannie
Publié 2016Texte -
6
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects par Wilbraham, Darren, Biglan, Kevin M., Svensson, Kjell A., Tsai, Max, Kielbasa, William
Publié 2020Texte -
7
-
8
Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults par Webb, Nicholas J. A., Wells, Thomas, Tsai, Max, Zhao, Zhen, Juhasz, Attila, Dudkowski, Caroline
Publié 2016Texte -
9
-
10
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor–Positive Allosteric Modulator, in Patients With Parkinson Disease par Wilbraham, Darren, Biglan, Kevin M., Svensson, Kjell A., Tsai, Max, Pugh, Melissa, Ardayfio, Paul, Kielbasa, William
Publié 2021Texte -
11
-
12
Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo‐ and Alprazolam‐Controlled Crossover Study par Wilbraham, Darren, Berg, Paul H., Tsai, Max, Liffick, Emily, Loo, Li Shen, Doty, Erin Gautier, Sellers, Edward
Publié 2019Texte -
13
A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationsh... par Goldsmith, Paul, Affinito, John, McCue, Maggie, Tsai, Max, Roepcke, Stefan, Xie, Jinhui, Gertsik, Lev, Macek, Thomas A.
Publié 2017Texte -
14
Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls par Pearlman, Eric M., Wilbraham, Darren, Dennehy, Ellen B., Berg, Paul H., Tsai, Max, Doty, Erin G., Kay, Gary G.
Publié 2020Texte -
15
Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine par Tsai, Max, Nery, Emel Serap Monkul, Kerr, Lisa, Khanna, Rashna, Komori, Mika, Dennehy, Ellen B., Wilbraham, Darren, Winner, Paul
Publié 2021Texte -
16
An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients par Gilleen, James, Farah, Yakub, Davison, Cate, Kerins, Sarah, Valdearenas, Lorena, Uz, Tolga, Lahu, Gez, Tsai, Max, Ogrinc, Frank, Reichenberg, Avi, Williams, Steve C., Mehta, Mitul A., Shergill, Sukhi S.
Publié 2018Texte